Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Retrospective Analysis of ALS Clusters Near Algae Blooms in North Carolina
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
11-019
To examine clinical differences between individuals with amyotrophic lateral sclerosis (ALS) who live near and far from harmful algal blooms (HABs) in North Carolina.

While 10% of ALS cases are associated with genetic mutations, the rest may have environmental causes. Higher than expected numbers of ALS cases have been identified near HABs in North Carolina using data from death certificates between 1999 and 2020 (unpublished). It is not clear why there might be more ALS cases near HABs. Blue-green algae produce toxins, such as β-methylamino-L-alanine, which are associated with neurotoxicity and ALS.

 

We hypothesize that there might be clinical differences in HAB-associated ALS and non-HAB-associated ALS, which may help to understand why this correlation exists and better manage HAB-associated ALS.

We will perform two retrospective cohort analyses comparing individuals with ALS who live far from HABs (more than 50 miles) and individuals with ALS who live near HABs (less than 50 miles). We will first analyze differences in demographics, genetic testing, and symptom onset using an existing RedCap database. We will analyze ALS progression using ALS Functional Rating Scale scores, forced vital capacity, and weight over time. For the second analysis using the Duke electronic medical record, we will examine the percentage of patients with ALS in each region and compare family history, comorbidities, medications, and socioeconomic status.
Preliminary results reveal that 16.3% of patients with ALS who live far from HABs have a family history of ALS or dementia, compared with 11.8% of those living near HABs.
This association suggests that higher than expected rates of ALS near HABs are not caused by genetic mutations.  Additional analyses are underway which we hope will shed light on the etiology of HAB-associated ALS and eventually lead to new treatments and methods of prevention.
Authors/Disclosures
Alexandra R. Linares, MD
PRESENTER
Ms. Linares has nothing to disclose.
Xiaoyan Li, MD (Duke University) Dr. Li has nothing to disclose.
Lisa Satterwhite (Duke University) No disclosure on file
Yuyao Sun, MD Dr. Sun has nothing to disclose.
Richard S. Bedlack, MD, PhD, FÂé¶¹´«Ã½Ó³»­ Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AB Science. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ALS Hope Foundation. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amylyx. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Capvision. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Carespace. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clene Nanomedicine. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Compassionate Care ALS. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eikonoclastes. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Haim Pharma. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Advances. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Care Strategy Partners. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for i3 Health. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Impossible Dream Machine. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InThought. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kaplan. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KeyQuest. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Launch Bio. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MJH HealthCare. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Med-IQ. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medicinova. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurosense. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharma. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prime Âé¶¹´«Ã½Ó³»­. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roon. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurosense. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for GenieUS Genomics. The institution of Dr. Bedlack has received research support from MediciNova. The institution of Dr. Bedlack has received research support from Healey Center. Dr. Bedlack has received publishing royalties from a publication relating to health care.